KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) Return on Invested Capital (2024 - 2025)

Historic Return on Invested Capital for Recursion Pharmaceuticals (RXRX) over the last 3 years, with Q3 2025 value amounting to 0.73%.

  • Recursion Pharmaceuticals' Return on Invested Capital fell 400.0% to 0.73% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.73%, marking a year-over-year decrease of 400.0%. This contributed to the annual value of 0.63% for FY2024, which is 900.0% up from last year.
  • As of Q3 2025, Recursion Pharmaceuticals' Return on Invested Capital stood at 0.73%, which was down 400.0% from 0.69% recorded in Q2 2025.
  • Over the past 5 years, Recursion Pharmaceuticals' Return on Invested Capital peaked at 0.58% during Q1 2025, and registered a low of 0.86% during Q1 2024.
  • In the last 3 years, Recursion Pharmaceuticals' Return on Invested Capital had a median value of 0.71% in 2025 and averaged 0.71%.
  • The largest annual percentage gain for Recursion Pharmaceuticals' Return on Invested Capital in the last 5 years was 2800bps (2025), contrasted with its biggest fall of -400bps (2025).
  • Over the past 3 years, Recursion Pharmaceuticals' Return on Invested Capital (Quarter) stood at 0.77% in 2023, then increased by 21bps to 0.61% in 2024, then dropped by -20bps to 0.73% in 2025.
  • Its last three reported values are 0.73% in Q3 2025, 0.69% for Q2 2025, and 0.58% during Q1 2025.